结外NK/T细胞淋巴瘤(鼻型)治疗进展
结外NK/T细胞淋巴瘤(鼻型)(ENKL)是与EB病毒相关、常累及结外的成熟T/NK细胞淋巴瘤。蒽环类化疗不推荐用于ENKL,尚无基于随机对照试验的标准治疗。局限期以放疗为核心(50-54 Gy,扩展受累部位放疗,IMRT/VMAT),支持序贯放化疗(含左旋天冬酰胺酶和/或铂类方案)。晚期推荐造血干细胞移植作为一线巩固,新药(包括免疫检查点抑制剂)正在研究中。
要点
- 蒽环类化疗不推荐用于治疗ENKL。
- 局限期患者放疗是推荐一线治疗的核心组分,剂量50-54 Gy,可考虑扩展受累部位放疗及IMRT/VMAT。
- 晚期ENKL推荐造血干细胞移植作为一线巩固治疗;含左旋天冬酰胺酶化疗是系统性ENKL一线治疗的关键组分。
核心结论
- 在当代ENKL治疗中,需要多学科协作来确定放疗、左旋天冬酰胺酶、铂类、新药和造血干细胞移植的最佳时机和顺序。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- ENKL与EB病毒相关且常累及结外,尽管地理分布有差异,西方国家与流行区(如东亚)的临床特征相似。
- 蒽环类化疗不推荐用于治疗ENKL,尚无基于随机对照试验结果建立的标准治疗。
- 局限期患者放疗是推荐一线治疗的核心组分,放疗剂量50-54 Gy、考虑肿瘤侵袭性的扩展受累部位放疗以及使用调强放疗或容积旋转调强放疗与放疗疗效相关。
- 同步放化疗已获临床试验结果支持,但越来越多的证据支持采用含左旋天冬酰胺酶和/或铂类抗癌药的序贯放化疗。
- 含左旋天冬酰胺酶化疗是系统性ENKL一线治疗的关键组分;造血干细胞移植推荐作为新诊断晚期ENKL的一线巩固治疗。
关键数值与推荐
- 放疗剂量为50-54 Gy;可考虑扩展受累部位放疗;可使用调强放疗或容积旋转调强放疗。
- 蒽环类化疗不推荐用于ENKL。
- 含左旋天冬酰胺酶和/或铂类的序贯放化疗获得越来越多证据支持。
- 造血干细胞移植推荐作为新诊断晚期ENKL的一线巩固治疗。
临床怎么用
- 局限期ENKL以放疗为核心,剂量50-54 Gy,可考虑扩展受累部位放疗及调强放疗或容积旋转调强放疗。
- 局限期可采用序贯放化疗,方案含左旋天冬酰胺酶和/或铂类。
- 系统性ENKL一线治疗含左旋天冬酰胺酶化疗;新诊断晚期患者推荐造血干细胞移植作为一线巩固。
- 新药(包括免疫检查点抑制剂)正在研究中,需多学科协作确定放疗、左旋天冬酰胺酶、铂类、新药和造血干细胞移植的最佳时机与顺序。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Extranodal natural killer/T-cell lymphoma, nasal type (ENKL) is a subtype of mature T- and natural killer cell lymphomas characterized by its association with Epstein-Barr virus and extranodal involvement. Although there is geographic variance in the frequency of ENKL, its clinical features are similar between Western countries and endemic areas, such as East Asia. Anthracycline-containing chemotherapy is not recommended to treat ENKL. No standard treatment has been established based on the results of randomized controlled trials. In patients with localized disease, radiotherapy is a core component of the recommended first-line therapy. Radiotherapy administered at 50 to 54 Gy, extended involved-site radiotherapy considering tumor invasiveness, and the use of intensity modulated radiation therapy or volumetric modulated arc therapy are associated with efficacy of radiotherapy. Although the use of concurrent chemoradiotherapy has been supported by the results of clinical trials, accumulating evidence supports the use of sequential chemoradiotherapy with non-anthracycline-containing regimens that include l-asparaginase and/or platinum anticancer agents. l-asparaginase-containing chemotherapy is a key component of first-line treatments for systemic ENKL. Hematopoietic stem cell transplantation is recommended as a front-line consolidation therapy for newly diagnosed advanced-stage ENKL. Newer agents including immune checkpoint inhibitors are being investigated for treating ENKL. In this modern ENKL treatment era, multidisciplinary efforts are needed to identify the best timing and sequencing of radiotherapy, l-asparaginase, platinum, newer agents, and hematopoietic stem cell transplantation.
引用
- Yamaguchi M, Suzuki R, Oguchi M, et al. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood. 2018. PMID: 29602763. doi:10.1182/blood-2017-12-791418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。